Collection-image

TOPICAL COLLECTIONS

Small Molecule Screening Strategies: Lead Identification and Validation

Submit Abstract

Guest Editor

Milka Kostic

Milka Kostic

Program Director, Dana-Farber Cancer Institute, Department of Cancer Biology, Chemical Biology

Dr. Milka Kostic is the Program Director, Chemical Biology at Dana-Farber Cancer Institute. In this role, Dr. Kostic supports a vibrant chemical biology program of about 120 scientists (faculty, postdocs, graduate students, staff scientists and technicians), who work tirelessly to develop chemistry-inspired research tools, platforms and strategies, to make new discoveries in basic biology, as well as translate these discoveries into improved clinical practice. Prior to Dana-Farber, Dr. Kostic was the Editor of Cell Chemical Biology and Structure for more than a decade, supporting and shaping chemical biology and structural biology communities. Dr. Kostic is a passionate advocate for chemical biology, and its transformative ability to accelerate basic and translational discoveries on the chemistry-biology-medicine continuum. She is also committed to promoting gender equality in society and science, and career development and well-being of early career researchers. Dr. Kostic has been lecturing and coaching scientists on career development and planning, social media use, presentation, and communication skills. Additionally, Dr. Kostic has written and presented on a range of chemical biology topics, most notably, chemical probe development and validation, covalent inhibitors and targeted protein degradation.

Collection Overview

The genomics revolution has resulted in a vast amount of knowledge about human physiology and how different diseases affect function. Additional technological advancements, such as transcriptomics and proteomics have pushed insights even further. However, translating these findings into new drugs has progressed less rapidly. One of the bottlenecks is the challenge of going from the identity of the most appropriate cellular target, to having a drug, usually a small molecule, that affect the biology of the target in a manner that corrects the disease phenotype. A type of strategy developed to address this challenge is high-throughput screening (HTS). HTS is used to identify small molecules that bind a target of interest, leading to desired change in target’s behavior (usually activity) and/or to cellular phenotype of interest. These methods commonly use robotic sample handling, small volumes, rapid data acquisition, and sophisticated software and compound library management systems, to conduct thousands, even millions of small scale experiments and identify the most promising hit compounds. Moreover, high-throughput methods to validated the hits in terms of their binding affinities, selectivity, in-cell target engagement, pharmacokinetic and pharmacodynamic properties, reactivity, and stability are also on the rise. This methods collection captures some of the work in this area, and it is certain to grow further as new advancements in HTS methods continue to be reported. It is a resource for anyone interested in drug discovery and development, as well as hit identification and validation

Editorial

Small Molecule Screening Strategies from Lead Identification to Validation

Small Molecule Screening Strategies from Lead Identification to Validation

0 Views

•

2023

•

Articles

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Abstracts

Sequence to Structure to Drug: Molecular Modeling and Docking in Small Molecule Discovery

Asimul Islam*1,

Gourav Chaudhir1

1Jamia Millia Islamia